KANJINTI
Google image searchProduct monograph
Active ingredient
trastuzumab, 420 MG/VIAL
DIN: 02496690
Dosage form(s): KIT, POWDER FOR SOLUTION
Route(s) of administration: INTRAVENOUS
Schedule: Prescription / Schedule D
Company: AMGEN CANADA INC
Date: 16-APR-2020
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FD — HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors (ATC, ATC/DDD)
- L01FD01 — TRASTUZUMAB (ATC/DDD)
Reference brand drug: Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera
